Alx Oncology Holdings (ALXO) Net Cash Flow (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Net Cash Flow data on file, last reported at $15.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 422.19% year-over-year to $15.9 million; the trailing twelve-month figure through Mar 2026 stood at $11.7 million (up 77.54% YoY), and the FY2025 full-year result was -$1.2 million, up 75.33% from the prior year.
• Net Cash Flow climbed to $15.9 million in Q1 2026, from -$7.1 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $15.9 million in Q1 2026 to a low of -$204.5 million in Q1 2022.
• A 5-year average of -$19.5 million and a median of -$232000.0 in 2022 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow tumbled 4586.41% in 2022 and surged 1316.38% in 2023, its largest moves.
• Tracing ALXO's Net Cash Flow over 5 years: stood at -$232000.0 in 2022, then surged by 1316.38% to $2.8 million in 2023, then sank by 48.09% to $1.5 million in 2024, then tumbled by 582.53% to -$7.1 million in 2025, then jumped by 325.08% to $15.9 million in 2026.
• Business Quant data shows ALXO's Net Cash Flow at $15.9 million in Q1 2026, -$7.1 million in Q4 2025, and $4.1 million in Q3 2025.